Bio Pharma Dive

JANUARY 6, 2023

The agency’s approval comes months after a large clinical trial showed the drug, called Leqembi, could slow the disease’s progression.

FDA Approval 342

FDA Approval Clinical Trials Clinical Trials Trials 342

XTalks

MARCH 9, 2023

Travere Therapeutics recently announced that their medication Filspari (sparsentan) received accelerated approval from the US Food and Drug Administration (FDA). Filspari is the first single molecule dual endothelin angiotensin receptor antagonist (DEARA) approved for this indication.

FDA Approval 95

FDA Approval Clinical Trials Clinical Trials Protein 95

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD).

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

XTalks

FEBRUARY 3, 2023

The decision was based on the results from a Phase I/II study, and continued approval is dependent upon the results of a confirmatory Phase III trial. Different types of TKIs have been approved to treat multiple cancers, including blood cancers.

FDA Approval 86

FDA Approval Protein Clinical Trials Clinical Trials 86

XTalks

JANUARY 6, 2023

Last week, the FDA approved a new infusible medication from TG Therapeutics for adults with relapsing forms of multiple sclerosis (MS), which include clinically isolated syndrome (CIS), relapsing-remitting (RR) MS, and active secondary progressive MS (SPMS).

FDA Approval 76

FDA Approval Clinical Trials Clinical Trials Antibody 76

XTalks

JANUARY 4, 2023

NexoBrid was already approved for use in 43 countries, including the European Union, India, Japan and others. This US FDA approval of NexoBrid validates our enzymatic technology platform. million milestone payment from Vericel due to the recent FDA approval of NexoBrid.

FDA Approval 89

FDA Approval Contamination Licensing Licensing 89

Pharmaceutical Technology

MARCH 1, 2023

The US Food and Drug Administration (FDA) has granted approval for Regeneron Pharmaceuticals and Sanofi ’s Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adult patients.

FDA Approval 245

FDA Approval Clinical Trials Clinical Trials Trials 245

World of DTC Marketing

AUGUST 27, 2021

SUMMARY: Over half of all clinical trial sites are outside the U.S. 87 % of all subjects in recent biologics trials were enrolled outside the U.S. DTC may or may not work for clinical trial enrollment it really depends on the condition and risk as judged by the patient.

Clinical Trials 187

Clinical Trials Clinical Trials Marketing Trials 187

Pharmaceutical Technology

FEBRUARY 17, 2023

In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage.

Clinical Trials 278

Clinical Trials Clinical Trials Trials Licensing 278

Pharmaceutical Technology

JULY 11, 2022

The US Food and Drug Administration (FDA) has granted approval for Pfizer and BioNTech’s supplemental Biologics License Application (sBLA) for their Covid-19 vaccine, Comirnaty, for adolescents aged 12 to 15 years.

FDA Approval 259

FDA Approval Vaccination Vaccine Licensing 259

Pharma Phorum

JULY 8, 2022

The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the clinical trial space. Hybrid or decentralised clinical trials (DCTs) have gained traction as technology, infrastructure and knowledge have evolved to support their use.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Regulation 100

XTalks

FEBRUARY 6, 2023

GlaxoSmithKline LLC (GSK) recently announced that the US Food and Drug Administration (FDA) approved Jesduvroq (daprodustat), a new once-a-day oral treatment for anemia due to chronic kidney disease (CKD).

FDA Approval 87

FDA Approval Hormones Clinical Trials Clinical Trials 87

Pharmaceutical Technology

SEPTEMBER 19, 2022

The US Food and Drug Administration (FDA) has awarded Accelerated Approval for bluebird bio ’s Skysona (elivaldogene autotemcel; eli-cel) for slowing neurologic dysfunction progression in early, active cerebral adrenoleukodystrophy (CALD) patients.

FDA Approval 246

FDA Approval Gene Therapy Gene Licensing 246

Bio Pharma Dive

AUGUST 2, 2021

The regulator cleared Saphnelo despite mixed clinical trial data, giving patients another option after the recent OK for a drug aimed at the autoimmune disease's severe side effects

FDA Approval 340

FDA Approval Clinical Trials Clinical Trials Regulation 340

XTalks

APRIL 27, 2022

Gilead’s Veklury (remdesivir) gets FDA approval to treat young children with COVID-19 and becomes the first and only approved COVID-19 treatment for children under 12. This is the only approved COVID-19 treatment for children under 12 years of age.

FDA Approval 97

FDA Approval In-Vitro Vaccination Vaccine 97

Delveinsight

AUGUST 13, 2021

Clinical trials are an essential part of the drug development process. Worldwide, more than 2 million clinical trials are registered and the number is steadily increasing over the past several years. What are Virtual Clinical Trials?

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

OCTOBER 4, 2022

Recently, Mallinckrodt announced that Terlivaz (terlipressin) has been approved by the US Food and Drug Administration (FDA) to treat adult patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function. Outcomes of Clinical Trials of Terlipressin.

FDA Approval 97

FDA Approval Clinical Trials Clinical Trials Trials 97

Pharmaceutical Technology

FEBRUARY 3, 2023

The US Food and Drug Administration (FDA) has granted approval to Amgen and AstraZeneca ’s Tezspire (tezepelumab-ekko) for self-administration using a single-use, pre-filled pen for severe asthma patients aged 12 years and above.

FDA Approval 147

FDA Approval Antibody Clinical Trials Clinical Trials 147

Pharmaceutical Technology

JULY 8, 2022

Specialised Therapeutics’ oral drug, Nerlynx (neratinib) has obtained the Philippines Food and Drug Administration approval to lower the recurrence or mortality risk in early-stage HER2-positive (HER2+) breast cancer patients. The trial demonstrated that after a median follow-up of 5.2

FDA Approval 246

FDA Approval HR Hormones Clinical Trials 246

XTalks

JANUARY 13, 2023

Medical imaging tech company Polarean Imaging has recently announced that the US Food and Drug Administration (FDA) has approved their drug-device combination product Xenoview (xenon Xe 129 hyerpolarized). Two More Devices Approved by the FDA Alongside Xenoview.

FDA Approval 100

FDA Approval Packaging Packaging Clinical Trials 100

Pharma Phorum

JANUARY 23, 2023

Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). The post BeiGene’s Brukinsa FDA approved for CLL/SLL appeared first on.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Trials 52

XTalks

OCTOBER 4, 2022

The US Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ Rolvedon (eflapegrastim-xnst) injection. This approval is a significant milestone for our development team and collaboration with Hanmi Pharmaceutical. Clinical Trials and Commercialization.

FDA Approval 90

FDA Approval Clinical Trials Clinical Trials Trials 90

Outsourcing Pharma

JANUARY 25, 2022

Clinical DevelopmentThe agency has given the go-ahead on an IND application for a study evaluating Ananda Scientificâs Nantheia ATL5, a candidate for treating opioid use disorder.

FDA Approval 105

FDA Approval Clinical Trials Clinical Trials Trials 105

XTalks

JANUARY 26, 2023

The US Food and Drug Administration (FDA) recently granted approval for the Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) based on the results from two Phase III clinical trials.

FDA Approval 87

FDA Approval Genetics Clinical Trials Clinical Trials 87

Bio Pharma Dive

JUNE 8, 2021

Two near identical clinical trials of Aduhelm yielded conflicting results, dividing experts and even FDA staff. A third, confirmatory study is required, but Biogen has until 2029 to finish it

FDA Approval 282

FDA Approval Clinical Trials Clinical Trials Trials 282

XTalks

JANUARY 9, 2023

recently announced in a press release that Sunlenca (lenacapavir) received approval from the US Food and Drug Administration (FDA) for use as a twice-yearly treatment option for people living with multi-drug resistant HIV (human immunodeficiency virus). Gilead Sciences, Inc.

FDA Approval 92

FDA Approval In-Vitro RNA Clinical Trials 92

Pharmaceutical Technology

MARCH 17, 2023

The US Food and Drug Administration (FDA) has granted approval for Novartis ’ combination therapy, Tafinlar (dabrafenib) and Mekinist (trametinib), to treat BRAF V600E low-grade glioma (LGG) in paediatric patients as young as one year.

FDA Approval 130

FDA Approval Clinical Trials Clinical Trials Trials 130

Pharmaceutical Technology

AUGUST 12, 2022

The US Food and Drug Administration (FDA) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (fam-trastuzumab deruxtecan-nxki) to treat unresectable or metastatic non-small cell lung cancer (NSCLC) in adults. In the trial, 1.9%

FDA Approval 264

FDA Approval Clinical Trials Clinical Trials Antibody 264

Pharmaceutical Technology

FEBRUARY 1, 2023

The US Food and Drug Administration (FDA) has granted approval for Ellipses Pharma’s investigational new drug (IND) application for EP0042 to treat acute myeloid leukaemia (AML). The post US FDA approves Ellipses Pharma’s IND for AML therapy appeared first on Pharmaceutical Technology.

FDA Approval 130

FDA Approval In-Vivo In-Vitro Trials 130

XTalks

SEPTEMBER 14, 2022

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. The product has been approved for use in adult patients for the temporary improvement of moderate to severe glabellar (frown) lines.

Botox 98

Botox FDA Approval Cosmetics Clinical Trials 98

XTalks

DECEMBER 27, 2022

Boorjian, MD, Carl Rosen Professor and Chair of the Department of Urology at Mayo Clinic, and lead investigator on the recent clinical trial of Adstiladrin, in the company’s press release. The Clinical Trial that Led to the Approval.

Gene Therapy 52

Gene Therapy FDA Approval Gene DNA 52

Pharmaceutical Technology

AUGUST 8, 2022

AstraZeneca and Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) has received expanded approval from the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.

FDA Approval 264

FDA Approval HR Hormones Clinical Trials 264

XTalks

OCTOBER 18, 2022

Global medical device company Nevro Corp has received US Food and Drug Administration (FDA) approval for the Senza HFX iQ spinal cord stimulation (SCS) system for the treatment of long-term or chronic pain. It is also pursuing a CE mark approval of the spinal cord stimulator in Europe.

FDA Approval 91

FDA Approval Big Data Containment Life Science 91

XTalks

FEBRUARY 3, 2023

The US Food and Drug Administration (FDA) has approved the first and only oral drug for the treatment of advanced or metastatic breast cancer in postmenopausal women or adult men with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) ESR1 mutations.

Bioavailability 88

Bioavailability FDA Approval Hormones Clinical Trials 88

Pharmaceutical Technology

FEBRUARY 13, 2023

Pfizer has received the US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Cibinqo (abrocitinib) to treat a type of atopic dermatitis (AD). Previously, it was approved to treat AD in adults aged 18 years and above.

FDA Approval 147

FDA Approval Trials Clinical Trials Clinical Trials 147

XTalks

AUGUST 24, 2022

The first clinical use of spinal cord stimulation was in 1967 for chronic pain management in cancer patients. Yesterday, Abbott announced that their Proclaim Plus spinal cord stimulation system received approval from the US Food and Drug Administration (FDA).

FDA Approval 97

FDA Approval Clinical Trials Clinical Trials Engineer 97

XTalks

MARCH 10, 2023

This US Food and Drug Administration (FDA)-approved drug was also awarded a rare pediatric disease priority review voucher. Skyclarys was approved based on the results of the MOXIe Part 2 clinical trial.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Engineer 52

XTalks

NOVEMBER 7, 2022

Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials. Regulatory Approvals for CTC-Based Assays in Oncology.

Clinical Trials 96

Clinical Trials Clinical Trials Trials FDA Approval 96

XTalks

JANUARY 25, 2023

Massachusetts-based TheracosBio has received US Food and Drug Administration (FDA) approval for diabetes med Brenzavvy (bexagliflozin) to help improve glycemic control in adults with type 2 diabetes. It is the first FDA-approved SGLT2 inhibitor for any animal species.

FDA Approval 52

FDA Approval Cosmetics Insulin Sales 52

XTalks

AUGUST 31, 2022

In this episode, Ayesha discussed the FDA approval of Axsome Therapeutics’ rapid-acting oral treatment Auvelity for the treatment of major depressive disorder (MDD). Read the full articles here: Axsome’s Auvelity Wins FDA Approval as First Rapid-Acting Oral Treatment for Depression.

Life Science 52

Life Science Gene Therapy FDA Approval Gene 52

BioPharma Reporter

MAY 5, 2022

Oramed Pharmaceuticals announced this week that it has enrolled 100% of the patients in the worldâs first Phase 3 study of oral insulin under FDA approved protocols.

Insulin 128

Insulin Clinical Trials Clinical Trials FDA Approval 128

Pharmaceutical Technology

AUGUST 29, 2022

The US Food and Drug Administration (FDA) has granted approval for Incyte ’s Pemazyre (pemigatinib) to treat adults with relapsed or refractory (r/r) myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.

FDA Approval 147

FDA Approval Clinical Trials Clinical Trials Trials 147

BioTech 365

JULY 7, 2022

Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial ??The

FDA Approval 52

FDA Approval Drugs Clinical Trials Clinical Trials 52